Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Aplenc

Showing results (171-180 of 254) with videos related to

Pageof 26
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2022
Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy AugmentationAbdelrahman H Elsayed, Xueyuan Cao, Amit K Mitra, et al.
Pediatric Blood & Cancer|March 12, 2015
Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology GroupTamara P Miller, Andrea B Troxel, Yimei Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2014
Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531Alan S Gamis, Todd A Alonzo, Soheil Meshinchi, et al.
Pediatric Blood & Cancer|May 7, 2015
Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology GroupKelly D Getz, Yimei Li, Todd A Alonzo, et al.
Blood Advances|January 23, 2023
SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemiaRichard J Marrero, Xueyuan Cao, Huiyun Wu, et al.
Pediatric Blood & Cancer|July 13, 2024
Healthcare utilization disparities among children with high-risk neuroblastoma treated on Children's Oncology Group clinical trialsJamie Shoag, Yimei Li, Kelly D Getz, et al.
Blood Advances|February 2, 2024
Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemiaOussama Abla, Rhonda E Ries, Tim Triche, et al.
Proteomics. Clinical Applications|November 1, 2021
Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelAAnneke D van Dijk, Fieke W Hoff, Yihua Qiu, et al.
Pediatric Blood & Cancer|May 12, 2020
Identifying relapses and stem cell transplants in pediatric acute lymphoblastic leukemia using administrative data: Capturing national outcomes irrespective of trial enrollmentViviane C Cahen, Yimei Li, Kelly D Getz, et al.
Pediatric Blood & Cancer|February 15, 2023
Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: A report from the Children's Oncology GroupKaren M Chisholm, Jenny Smith, Amy E Heerema-McKenney, et al.
Pageof 26

Showing results (171-180 of 254) with videos related to

Sort By:
Pageof 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2022
Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy AugmentationAbdelrahman H Elsayed, Xueyuan Cao, Amit K Mitra, et al.
Pediatric Blood & Cancer|March 12, 2015
Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology GroupTamara P Miller, Andrea B Troxel, Yimei Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2014
Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531Alan S Gamis, Todd A Alonzo, Soheil Meshinchi, et al.
Pediatric Blood & Cancer|May 7, 2015
Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology GroupKelly D Getz, Yimei Li, Todd A Alonzo, et al.
Blood Advances|January 23, 2023
SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemiaRichard J Marrero, Xueyuan Cao, Huiyun Wu, et al.
Pediatric Blood & Cancer|July 13, 2024
Healthcare utilization disparities among children with high-risk neuroblastoma treated on Children's Oncology Group clinical trialsJamie Shoag, Yimei Li, Kelly D Getz, et al.
Blood Advances|February 2, 2024
Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemiaOussama Abla, Rhonda E Ries, Tim Triche, et al.
Proteomics. Clinical Applications|November 1, 2021
Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelAAnneke D van Dijk, Fieke W Hoff, Yihua Qiu, et al.
Pediatric Blood & Cancer|May 12, 2020
Identifying relapses and stem cell transplants in pediatric acute lymphoblastic leukemia using administrative data: Capturing national outcomes irrespective of trial enrollmentViviane C Cahen, Yimei Li, Kelly D Getz, et al.
Pediatric Blood & Cancer|February 15, 2023
Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: A report from the Children's Oncology GroupKaren M Chisholm, Jenny Smith, Amy E Heerema-McKenney, et al.
Pageof 26